NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Revolution Medicines, Inc. RVMD
8 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 8-year series below
Revenue $B
Net income $B
FY2025 · Revenue 0.0 · Net income -1.1
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2023 · Operating -4207.1% · Net -3768.3%
ROE
FY2025 · ROE -58.1%
Each USD of equity lost 58 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Operating income $B | −1.2 | −0.7 | −0.5 | −0.3 | −0.2 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | −1.2 | −0.7 | −0.5 | −0.3 | −0.2 | −0.1 | −0.1 | −0.0 |
| Income tax $B | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | · |
| Net income $B | −1.1 | −0.6 | −0.4 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.9 | −0.6 | −0.4 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 |
| EPS, diluted $ | −5.95 | −3.58 | −3.86 | −3.08 | −2.57 | −2.01 | −22.33 | −21.24 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | −0 | · | · |
| ROE % | −58.1 | −29.3 | −34.8 | −38.6 | −34.7 | −67.2 | · | · |
| Shares out B | 0.20 | 0.19 | 0.16 | 0.09 | 0.07 | 0.07 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 46 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2018